Literature DB >> 35595309

STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.

Uri Rozovski1,2,3, Ivo Veletic1, David M Harris1, Ping Li1, Zhiming Liu1, Preetesh Jain1, Taghi Manshouri1, Alessandra Ferrajoli1, Jan A Burger1, Prithviraj Bose1, Phillip A Thompson1, Nitin Jain1, William G Wierda1, Srdan Verstovsek1, Michael J Keating1, Zeev Estrov4.   

Abstract

Pentraxin-related protein 3 (PTX3), commonly produced by myeloid and endothelial cells, is a humoral pattern recognition protein of the innate immune system. Because PTX3 plasma levels of patients with chronic lymphocytic leukemia (CLL) are high and most circulating cells in patients with CLL are CLL cells, we reasoned that CLL cells produce PTX3. Western immunoblotting revealed that low-density cells from seven of seven patients with CLL produce high levels of PTX3, flow cytometry analysis revealed that the PTX3-producing cells are B lymphocytes coexpressing CD19 and CD5, and confocal microscopy showed that PTX3 is present in the cytoplasm of CLL cells. Because STAT3 is constitutively activated in CLL cells, and because we identified putative STAT3 binding sites within the PTX3 gene promoter, we postulated that phosphorylated STAT3 triggers transcriptional activation of PTX3. Immunoprecipitation analysis of CLL cells' chromatin fragments showed that STAT3 Abs precipitated PTX3 DNA. STAT3 knockdown induced a marked reduction in PTX3 expression, indicating a STAT3-induced transcriptional activation of the PTX3 gene in CLL cells. Using an EMSA, we established and used a dual-reporter luciferase assay to confirm that STAT3 binds the PTX3 gene promoter. Downregulation of PTX3 enhanced apoptosis of CLL cells, suggesting that inhibition of PTX3 might benefit patients with CLL.
Copyright © 2022 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35595309      PMCID: PMC9308680          DOI: 10.4049/jimmunol.2101105

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  60 in total

Review 1.  Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors.

Authors:  T Hirano; K Ishihara; M Hibi
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

2.  Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications.

Authors:  Tamar Tadmor; Lev Shvidel; Ariel Aviv; Rosa Ruchlemer; Osnat Bairey; Mona Yuklea; Yair Herishanu; Andre Braester; Naomi Rahimi-Levene; Naomi Levene; Fiona Vernea; Jonathan Ben-Ezra; Jacob Bejar; Aaron Polliack
Journal:  Cancer       Date:  2013-02-19       Impact factor: 6.860

3.  The cytoplasmic tyrosine motifs in full-length glycoprotein 130 have different roles in IL-6 signal transduction.

Authors:  J Schmitz; H Dahmen; C Grimm; C Gendo; G Müller-Newen; P C Heinrich; F Schaper
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

4.  Chromatin Remodeling Factor BRG1 Regulates Stemness and Chemosensitivity of Glioma Initiating Cells.

Authors:  Debolina Ganguly; Michelle Sims; Chun Cai; Meiyun Fan; Lawrence M Pfeffer
Journal:  Stem Cells       Date:  2018-11-12       Impact factor: 6.277

Review 5.  Infection and immunity in chronic lymphocytic leukemia.

Authors:  S Tsiodras; G Samonis; M J Keating; D P Kontoyiannis
Journal:  Mayo Clin Proc       Date:  2000-10       Impact factor: 7.616

6.  STAT3 serine 727 phosphorylation influences clinical outcome in glioblastoma.

Authors:  Guo-Shi Lin; Yu-Peng Chen; Zhi-Xiong Lin; Xing-Fu Wang; Zong-Qing Zheng; Long Chen
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

7.  STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis.

Authors:  Ping Li; David Harris; Zhiming Liu; Uri Rozovski; Alessandra Ferrajoli; Yongtao Wang; Carlos Bueso-Ramos; Inbal Hazan-Halevy; Srdana Grgurevic; William Wierda; Jan Burger; Susan O'Brien; Stefan Faderl; Michael Keating; Zeev Estrov
Journal:  Mol Cancer Res       Date:  2014-05-16       Impact factor: 5.852

8.  Elevated Pentraxin 3 in bone metastatic breast cancer is correlated with osteolytic function.

Authors:  Bongkun Choi; Eun-Jin Lee; Da-Hyun Song; Sung-Chul Yoon; Yeon-Ho Chung; Youngsaeng Jang; Sang-Min Kim; Youngsup Song; Sang-Wook Kang; Seung-Yong Yoon; Eun-Ju Chang
Journal:  Oncotarget       Date:  2014-01-30

Review 9.  The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis.

Authors:  Rémi Porte; Sadaf Davoudian; Fatemeh Asgari; Raffaella Parente; Alberto Mantovani; Cecilia Garlanda; Barbara Bottazzi
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

10.  Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition.

Authors:  Tao Song; Cong Wang; Cheng Guo; Qingguang Liu; Xin Zheng
Journal:  J Cancer       Date:  2018-06-23       Impact factor: 4.207

View more
  1 in total

1.  Amaryllidaceae Alkaloids Decrease the Proliferation, Invasion, and Secretion of Clinically Relevant Cytokines by Cultured Human Colon Cancer Cells.

Authors:  Veronique Mathieu; Breana Laguera; Marco Masi; Sara Adriana Dulanto; Tanner W Bingham; Lucas W Hernandez; David Sarlah; Antonio Evidente; Denis L J Lafontaine; Alexander Kornienko; Michelle A Lane
Journal:  Biomolecules       Date:  2022-09-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.